QS Research · Michael Burry's Scion Capital analyst template · 2006
NOVARTIS AG (NVS)
As of 2026-11-20 · 11/15 boxes filled from SEC filings and market data
Report price $151.22 (close 2026-11-19); latest close $150.47 (2026-11-20), -0.5% since the report; figures re-marked at the latest close
Conclusion: WATCH
Conviction low · base case +90% · downside -32% · upside +101%
At $151.22 Novartis is priced for modest durability, not a re-rating: 20.6x FY2025 net income and 17.3x FY2025 EBIT, a 5.8% EBIT yield against a 5.5% WACC, with ROIC of 23.1% and a 6.1% FCF yield. The multiple is cheap because the largest patent expiry in company history is still eroding US sales and two Phase III misses removed near-term pipeline offsets. That discount is defensible, but the gap to peers is peer-set rather than Novartis-specific. The base case is $285.56, +88.8%, on the P/E at 38.9x, the peer median P/E across nine peers spanning 12.9x to 133.5x. The upside case is $302.44, +100.0%, on the base case's multiple on +10% earnings. The downside case is $102.83, -32.0%, on -20.0% earnings at a compressed P/E of 17.51x. Both the base and the upside sit far above today's price, yet neither is a company-specific anchor and the downside is not protected, so the call is WATCH at low conviction.
Key numbers
- Share price: $150.47
- Market cap: $287.12B
- Latest financial period: TTM to Dec 31, 2025
- P/E (FY Dec 2025): 20.5x
- FCF yield: 6.1%
- Price / book: 6.23x
- EV / FCF (FY Dec 2025): 17.3x
- ROIC (FY Dec 2025): 23.1%
- WACC: 5.5%
- Economic profit spread: +17.5 pts
The 15 boxes
- ✓ 1. Long-form business notes
Novartis is now a pure innovative-medicines company: FY2025 net sales from continuing operations were USD 54.5B, split across oncology USD 16.8B, immunology USD 10.3B, cardiovascular/renal/metabolic USD 9.0B, neuroscience USD 6.0B and established brands USD 12.5B. The oldest report here, FY2020, shows a different two-division company—Innovative Medicines USD 39.0B plus Sandoz USD 9.6B—and the Sandoz spin-off completed October 3, 2023 removed Sandoz, so FY2020 and FY2025 sales are not like-for-like. FY2025 growth was concentrated in Kisqali, Kesimpta, Pluvicto and Scemblix, offset by generic erosion in Entresto, Promacta/Revolade and Tasigna; the FY2025 operating margin was 32.4% and core operating margin 40.1%, with free cash flow of USD 17.6B.
- ✓ 2. Competitive advantage
The sources support a large, cash-generative R&D organization but not an explicit durable moat: FY2025 gross profit was $42.98B and operating cash flow $19.14B, with operating income positive every year FY2020-FY2025. The 20-F bases protection on intellectual property and regulatory exclusivities while describing intense competition from major pharma, regional/national firms, generics/biosimilars and new tech entrants, and it says generic/biosimilar entry may follow expiry or successful IP challenges. R&D is long (10-15 years) and risky, so the advantage is not presented as permanent.
- ✓ 3. 10-Q takeaways
Q3 2026 net sales rose 4% USD and 4% cc to USD 14.522bn, with volume +14 pp partly offset by generic competition -9 pp; US +7%, rest of world +3%. Operating income fell 59% to USD 1.843bn and margin to 12.7% on a USD 1.9bn del-desiran IPR&D impairment and higher other expense, while core operating income rose 11% to USD 6.036bn and core margin rose to 41.6%. Cash was lower: Q3 operating cash flow USD 5.503bn (-16%) and FCF USD 5.111bn (-18%); 9M net debt rose to USD 37.4bn and the company used USD 4.8bn net for treasury shares plus a USD 9.1bn annual dividend.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ○ 9. Insider trading interpretation
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.